Immunic, Inc. (IMUX) Financials

IMUX Assets vs Liabilities

DateAssetsLiabilities
June 30, 2026 159.2 million 31.6 million
March 31, 2026 189.7 million 38.5 million
Dec. 31, 2025 24.1 million 30.7 million
Sept. 30, 2025 40.7 million 30.2 million

IMUX Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -31.2 million 6.8 million
March 31, 2026 -17.3 million 4.5 million
Dec. 31, 2025 -19.3 million 1.3 million
Sept. 30, 2025 -20.2 million 3.6 million

IMUX Net Income

No data available :(

IMUX Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 155.1 million 328000 239000
March 31, 2026 186.6 million - 421000
Dec. 31, 2025 15.5 million 107000 107000
Sept. 30, 2025 35.1 million - 792000

IMUX Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 42.5 million
March 31, 2026 30.1 million
Dec. 31, 2025 12.0 million
Sept. 30, 2025 19.4 million

IMUX Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 249000 25.9 million 9.4 million -
March 31, 2026 2000 25.6 million 7.6 million -
Dec. 31, 2025 11000 19.1 million 4.3 million -
Sept. 30, 2025 67000 20.0 million 6.0 million -

IMUX Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 33000
Dec. 31, 2025 - 42000
Sept. 30, 2025 - -

IMUX

Price: $16.83

52 week price:
5.06
16.83

Earnings Per Share: -3.67 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 562646

Market Capitalization: 217.4 million

Links: